穴位贴敷治疗实证痛经的疗效观察及对前列腺素的影响

目的:观察穴位贴敷治疗实证痛经的临床疗效及对前列腺素的影响.方法:将原发性痛经的实证患者随机分为贴敷组和药物组,贴敷组31例使用中药(制南星、三棱、莪术等)在中极、关元、气海穴处进行贴敷治疗;药物组30例口服田七痛经胶囊治疗.在治疗前后分别观察痛经的疼痛程度及持续时间的积分,测定外周血前列腺素F_(2α)(PGF_(2α))与前列腺素E_2(PGE_2)含量.结果:贴敷组总有效率为93.5%,明显优于药物组的73.3%(P<0.05);两组患者治疗后症状积分均较治疗前明显降低(均P<0.01),且贴敷组症状改善程度较药物组显著(P<0.01);贴敷组可明显升高原发性痛经患者外周血中PGE_2含量(P<0.01),明显降低外周血中PGF_(2α)含量及PGF_(2α)/PGE_2比值(均P<0.01).结论:穴位贴敷治疗实证原发性痛经有较好的疗效,临床值得推广.穴位贴敷对原发性痛经患者前列腺素的合成有良性调节作用.

Observation on therapeutic effect of acupoint application on dysmenorrhea of excess syndrome and effect on prostaglandins

Objective To observe therapeutic effect of acupoint application on dysmenorrhea of excess syndrome and its effect on prostaglandins. Methods The patients with primary dysmenorrhea of excess syndrome were randomly divided into an application group and a medication group. The application group of 31 cases were treated with application of Chinese medicine composed of Zhinanxing (Rhizoma Arisaematis), Sanleng (Rhizoma Sparganii) , Ezhu (Rhizoma Zedoariae) , etc. at Zhongji (CV 3) , Guanyuan (CV 4) , Qihai (CV 6) ; and the medication group of 30 cases were treated with oral administration of Tianqi Tongjing Capsules. The scores for the pain degrees and the duration of dysmenorrhea were observed and prostaglandin F_(2α)(PGF_(2α)) and prostaglandin E_2(PGE_2) contents in peripheral blood were determined before and after treatment. Results The total effective rate of 93. 5% in the application group was significantly better than 73. 3% in the medication group (P<0. 05) ; after treatment, the scores of the symptoms were significantly decreased in the two groups (both P<0. 01) , with more obvious improvement in the application group than the medication group (P<0. 01). The PGE_2 content was significantly increased, and the PGF_(2α) content and PGF_(2α)/PGE_2 were significantly decreased in the application group (all P<0. 01). Conclusion Acupoint application has a better therapeutic effect on dysmenorrhea of excess syndrome and has benign regulative action on synthesis of prostaglandins in the patients with primary dysmenorrhea.